Evolutec Group PLC
04 December 2006

Monday 4 December 2006



Evolutec Group plc
('Evolutec' or 'the Company')

Primary Endpoint Not Met in Phase IIb rEV131 Trial in Allergic Rhinitis

Evolutec Group plc (AIM: EVC), the biopharmaceutical company developing novel
products for the treatment of allergic, inflammatory and autoimmune diseases,
announces that no significant differences were observed between rEV131 and
placebo in the Phase IIb trial in allergic rhinitis and the primary endpoint was
therefore not met.

Further clinical results with rEV131 from a second unrelated indication,
inflammation following cataract surgery, are anticipated early next year. Once
these clinical results are received the Company will review its strategy for
rEV131. This will be presented at the time of the preliminary results on 27
February 2007.

Mark Carnegie Brown, Chief Executive of Evolutec, said:

'This is tremendously disappointing for Evolutec and its shareholders. We will
review our intended programmes with rEV131 once the post-cataract results are
received early next year and in the interim will continue to progress rEV576.'

Enquiries:

Evolutec 0118 922 4480
Mark Carnegie Brown, Chief Executive Officer
Nicholas Badman, Chief Financial Officer

www.evolutec.co.uk


Financial Dynamics 020 7831 3113
David Yates
Ben Brewerton


Notes for Editors:

About Evolutec

Evolutec, which is based in Reading, UK, is a clinical stage biopharmaceutical
company with a focus on allergy, inflammation and auto-immune diseases.

rEV576, the Company's second product development candidate is a complement
inhibitor which has demonstrated preclinical activity against the autoimmune
diseases myasthenia gravis and Guillain-Barre Syndrome, asthma and acute
myocardial infarction ('AMI') (heart attack). Evolutec has established a
research collaboration with Case Western Reserve University, Cleveland, Ohio, to
undertake further preclinical work with rEV576 in myasthenia gravis. The Company
expects to commence clinical trials with rEV576 in 2007.

The rights to Evolutec's vaccine technology for animals are partnered with
Merial. Merial is currently undertaking work in tick-borne diseases.

Evolutec is listed on the AIM market of the London Stock Exchange and develops
therapeutics originally isolated from the saliva of ticks. The tick remains
undetected by its hosts, including humans, by injecting an array of molecules
into the skin that suppresses host immunity. These stealth molecules have
undergone millions of years of natural evolution to select a promising efficacy,
potency and safety profile. Evolutec employs the tick's evolutionary stealth
technology to offer the potential of treating human diseases.


This information is provided by RNS
The company news service from the London Stock Exchange

27p today
Well blow me, it appears the placebo is better; - since it costs less and has absolutely no side effects - unless you drop the glass of water on your foot and slip thereby breaking a toe or twisting your ankle. Ouch.
I bought some of these at 1.22 their near-peak, but it was quite few; just goes to show eh?
What it shows is that PhI trials are pretty useless, which is to be expected in fairness; thank goodness they didn't ask shareholders to fund PhIII.
Tick this one off, I think.

Oh dear, oh dear -bad enough to open one tin of peaches and find baked-beans...now we discover the jar of face-cream is axle-grease.
Story 03Jan2007 the cataract treatment is no use (sorry to be brutal).
-I think this raises questions ...how the execs can raise money against a product-stream (so-far) with zero efficagy? If any product is "real", that is because a headache-tablet reduces your headache - if it's like stubbing yr toe (taks the mind off..), then the execs are committing close-to fraudulent claims, since it is not a cure in any sense, yet doing potential foot-damage in the process.
-Don't know what to make of this company - it's worse than the horses, and I know nowt about them.

Close at 15.5p today...I think it is a placebo...going below 10p soon

with 30p of cash looks like you might be wrong...now 21.5

all gone quiet on here. What you guys make of the major houses recent January interest in the stock - such mass investement from these guys can only mean one thing? Results out on Tuesday too - seems like a bargain?? Loaded up on the chance of positive news, what with the apointment of Numis too, cant see anything other than positive!!

Frankly I see very little value in this co UNTIL their next product gets a little further along. Investors have to realise that small Bio's really shouldn't be listed and it is bound to be a rocky ride - either it works and they have a product that's worth millions....or not.
At earlier levels (over 1) it was clearly all hope - the real value is probably twice current sp (on account of cash alone I sus;pect), but most investors will only buy when the trials are declared - and whilst that makes sense it is the difference between a 10-bagger and maybe 4x - at current levels your investment (in money-value terms) is pretty safe...however, poor management could burn through this and maybe that's the issue - some execs should go....they aren't up to it.

[[EDIT:- June 2007 - it seems the co will return cash to shareholders about 21p/share later in 2007, so expect this to be discounted right up to the final days - when wide-boys buy ots and make maybe 2p per share x a few million! A sorry end to an exciting prospect which didn't quite make it - not sure about the other products, they seem to have gone off the boil, etc.]]

A YEAR Later - sp up 5% to 20p (mid).
And it is evident that the pharma-company is having a near-death experience.
They appear to be trying to use their listing to attract another business, a side-ways takeover....or "Reverse"...?
Quite a flurry of buying today - with just 4k of sells.
Does someone know "something's up"?

. . . . . . Did anything happen to the idea of returning shareholder cash?
Of course not, - execs need a business to be directors of - to keep their salaries flowing....Grr!

Let's not forget this company stroked up their sp to over 1.

All IMHO - - please DYOR.
EDIT-22Aug08 - sp up again to 26p - something odd